Description
LGD-4033 (Ligandrol) Research Chemical
LGD-4033, developed by Ligand Pharmaceuticals, is a selective androgen receptor modulator (SARM) that binds AR with high affinity and selectivity. It has been studied in Phase II clinical trials (Basaria et al.) for muscle wasting — the only SARM outside of Enobosarm (Ostarine) to reach this stage of clinical development.
Research Applications
- Muscle wasting models: cachexia, age-related sarcopenia
- Bone density research in osteoporosis models
- AR binding affinity and selectivity studies
- Pharmacokinetic research (t½ ~24–36h in rodents)
Product Specifications
- Purity: ≥98% HPLC confirmed
- Identity: Mass spectrometry verified (MW: 338.25)
- Certificate of Analysis: Third-party, every batch
- Form: Lyophilized powder, sealed glass vial
- Storage: -20°C, 24 months lyophilized
For Research Use Only (RUO). Not for human consumption.
